Summary
In a placebo controlled double-blind cross-over study, the cardiovascular and antidepressant effects of three weeks' treatment with mianserin (30–80 mg daily) and trazodone (150–400 mg daily) were studied in depressed patients who had co-existant cardiac disease.
In 14 of the 16 patients, no haemodynamic deterioration occurred with either drug. Two patients withdrew from the study. One with coronary artery disease, whose concomitant medication included a calcium-antagonist and a beta-adrenoceptor blocker and who developed severe postural hypotension after his first dose of trazodone while the other had an increased frequency of transient cerebral ischaemic attacks with both mianserin and trazodone, but not with placebo.
Mianserin and trazodone are comparable for both antidepressant efficacy and paucity of cardiovascular effects. Although unwanted effects were generally mild, the incidence of dizziness was greater in those patients receiving trazodone. Caution is advised, however, when prescribing either drug to patients with transient cerebral ischaemic attacks or those with coronary artery disease receiving medication.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Al-Yassiri MM, Ankier SI, Bridges PK (1981) Minireview: Trazodone — A new antidepressant. Life Sci 28: 2449–2458
Ayd FJ, Settle EC (1982) Trazodone: A novel, broadspectrum antidepressant. Trazodone. In: Ban TA, Silvestrini B (eds) Modern problems in pharmacopsychiatry, vol 18. Karger, Basel, pp 49–69
Lisciani R, Compana A, Scorza Barcellona P (1978) Comparative cardiovascular toxicity of trazodone and imipramine in the rat. Arch Toxicol 1 [Suppl]: 169–172
Domino EF (1974) Discussion on pharmacological features of trazodone. Trazodone. In: Ban TA, Silvestrini B (eds) Modern problems of pharmacopsychiatry, vol 9. Karger, Basel, pp 52–55
Clements-Jewery S, Robson PA, Chidley LJ (1980) Biochemical investigations into the mode of action of trazodone. Neuropharmacol 19: 1165–1173
Gershon S, Newton R (1980) Lack of anticholinergic side-effects with a new anti-depressant — Trazodone. J Clin Psychiatry 41: 100–104
McGraw BF, Hemberger JA, Smith AL, Schroeder JS (1981) Variability of exercise performance during long-term placebo treatment. Clin Pharmacol Ther 30: 321–327
Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6: 278–296
Ankier SI, Martin BK, Rogers MS, Carpenter PK, Graham C (1981) Trazodone — A new assay procedure and some pharmacokinetic parameters. Br J Clin Pharmacol 11: 505–509
Thoma JJ, Bardo PB, Kozak CM (1979) Tricyclic antidepressants in serum by a Clin-Elut TM Column extraction and HPLC analysis. Ther Drug Monit: 335–358 (Modified from Chromatography)
Coull DC, Crooks J, Dingwall-Fordyce I, Scott A, Weir RD (1970) Amitriptyline and cardiac disease: Risk of sudden death identified by monitoring system. Lancet 2: 590–591
Moir DC, Crooks J, Cornwell WB, et al. (1972) Cardiotoxicity of amitriptyline. Lancet 2: 561–564
Moir DC, Dingwall-Fordyce I, Weir RD (1973) Medicines evaluation and monitoring group: A follow-up study of cardiac patients receiving amitriptyline. Eur J Clin Pharmacol 6: 98–101
Glassman AH, Johnson LL, Giardina E-GV, et al. (1983) The use of imipramine in depressed patients with congestive heart failure. J Am Med Assoc 250: 1997–2001
Edwards JG, Goldie A (1983) Mianserin, maprotiline and intracardiac conduction. Br J Clin Pharmacol 15 [suppl 2]: 249–254
Burckhardt D, Raeder E, Muller V, Imhof P, Neubauer H (1978) Cardiovascular effects of tricyclic and tetracyclic antidepressants. J Am Med Assoc 239: 213–216
Janowsky DS (1983) Trazodone increases ventricular arrhythmias. Clin Pharmacol Ther 33: 240
Janowsky D, Curtis G, Zisook S, Kuhn K, Resovsky K, Le Winter M (1983) Ventricular arrhythmias possibly aggravated by trazodone. Am J Psychiatry 140: 796–797
Vlay SC, Friedling S (1983) Trazodone exacerbation of VT. Am Heart J 106: 604
Lippmann S, Bedford P, Manshadi M, Mather S (1983) Trazodone cardiotoxicity. Am J Psychtry 140: 1383
Whiteford H, Klug P, Evans L (1984) Disturbed cardiac function possibly associated with mianserin therapy. Med J Aust 140: 166–167
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bucknall, C., Brooks, D., Curry, P.V.L. et al. Mianserin and trazodone for cardiac patients with depression. Eur J Clin Pharmacol 33, 565–569 (1988). https://doi.org/10.1007/BF00542488
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00542488